Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2015-11-09
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of the
combination of tesevatinib and trastuzumab in subjects with HER2-positive metastatic breast
cancer